Product logins

Find logins to all Clarivate products below.


Relacorilant

Learn how relacorilant is changing the ovarian cancer and hypercortisolism landscapes.

What is relacorilant and what sets it apart

Relacorilant is emerging as a promising therapeutic candidate in two high-need areas: platinum-resistant ovarian cancer and endogenous hypercortisolism (Cushing syndrome). By modulating the activity of cortisol — a hormone implicated in both tumor resistance and metabolic dysfunction — relacorilant offers a novel mechanism of action setting it apart from existing treatments.

Relacorilant has the potential to be first in class for both platinum-resistant ovarian cancer and Cushing syndrome. As a result, it is poised to make a dual impact in 2026, potentially redefining treatment paradigms for patients with limited effective options.

About relacorilant

  • Company: Corcept Therapeutics Inc
  • Type: Selective glucocorticoid receptor antagonist (SGRA)
  • Usage: Daily oral administration to treat platinum-resistant ovarian cancer, Cushing syndrome and hypercortisolism associated with adrenal adenoma or hyperplasia
    Also being evaluated for prostate cancer
  • When will relacorilant be available?
    Expected launch 2025: United States (Cushing syndrome)
    Expected launch 2026: European Union, United States (ovarian cancer)

Relacorilant sales and success forecasts

$150m
expected sales for ovarian cancer in the G7 markets in 2031
95%
probability of success for relacorilant in the United States

Relacorilant is exciting because it's agnostic to tumor microenvironment. Patients without a marker have no treatment options except for chemotherapy. This gives them the opportunity to get something else.

Medical oncologist United States

Drugs in the 2026 list

BioWorld by Clarivate Highlights Gaps in Women’s Health Research and Investment in New Special Series BioWorld by Clarivate Highlights Gaps in Women’s Health Research and Investment in New Special Series
News November 21, 2024
BioWorld by Clarivate Highlights Gaps in Women’s Health Research and Investment in New Special Series

New seven-part series explores disparities in care, funding and innovation impacting half the world’s population London, UK, November 21, 2024– BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider…

Rediscovering women’s health Rediscovering women’s health
Report
Rediscovering women’s health

Explore global data, funding gaps, and opportunities to advance equity and innovation in women’s health worldwide.

Companies To Watch: The $1 Trillion Opportunity: Rethinking Investment in Women’s Health Companies To Watch: The $1 Trillion Opportunity: Rethinking Investment in Women’s Health
Webinar
Companies To Watch: The $1 Trillion Opportunity: Rethinking Investment in Women’s Health

Despite representing half the global population, women continue to face systemic inequities in health research and funding. Conditions that disproportionately affect women—such as migraines, cognitive disorders, and maternal health—remain underfunded, while clinical guidelines often fail to account for female-specific risk factors. Yet momentum is growing: landmark studies, targeted funding initiatives, and new policy frameworks are...

chevron_left
chevron_right